novel
coronaviru
newli
emerg
viru
antibodi
respons
infect
patient
remain
larg
unknown
clinic
valu
antibodi
test
fulli
demonstr
total
patient
confirm
infect
enrol
serial
plasma
sampl
n
collect
hospit
period
test
total
antibodi
ab
igm
igg
use
immunoassay
dynam
antibodi
progress
sever
diseas
analyz
among
patient
seroconvers
rate
ab
igm
igg
respect
twelv
patient
seroconvert
blood
sampl
earli
stage
ill
collect
seroconvers
sequenti
appear
ab
igm
igg
median
time
day
respect
presenc
antibodi
among
patient
first
day
ill
rapidli
increas
ab
igm
igg
respect
sinc
day
onset
contrast
posit
rate
rna
decreas
sampl
collect
day
day
combin
rna
antibodi
detect
significantli
improv
sensit
pathogen
diagnosi
patient
p
even
earli
phase
sinc
onset
p
moreov
higher
titer
ab
independ
associ
wors
clinic
classif
p
antibodi
detect
offer
vital
clinic
inform
cours
infect
find
provid
strong
empir
support
routin
applic
serolog
test
diagnosi
manag
patient
sinc
earli
decemb
februari
case
coronaviru
diseas
caus
novel
coronaviru
infect
death
case
infect
report
countri
major
occurr
china
world
health
organ
declar
public
health
emerg
intern
concern
januari
public
health
author
around
world
react
promptli
prevent
spread
viru
accord
recent
report
patient
incub
period
day
fever
cough
fatigu
common
symptom
wherea
nasal
congest
runni
diarrhea
note
small
part
patient
sever
case
might
rapidli
progress
acut
respiratori
distress
syndrom
ard
septic
shock
difficulttotackl
metabol
acidosi
bleed
coagul
dysfunct
note
patient
mild
atyp
symptom
initi
even
sever
critic
case
chest
comput
tomographi
featur
patient
character
groundglass
opac
bilater
patchi
shadow
laboratori
test
report
patient
lymphopenia
patient
elev
creactiv
protein
howev
abovement
clinic
laboratori
characterist
easili
distinguish
pneumonia
induc
infect
common
respiratori
tract
pathogen
influenza
viru
streptococcu
pneumonia
mycoplasma
pneumonia
time
accur
diagnosi
infect
cornerston
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
effort
provid
appropri
treatment
patient
limit
spread
viru
ultim
elimin
viru
human
societi
current
viral
rna
detect
sever
polymeras
chain
reaction
pcr
base
technic
almost
way
confirm
diagnosi
infect
practic
hand
rna
test
base
throat
nasopharyng
swab
brought
neglig
falseneg
risk
report
posit
rate
vari
differ
swab
specimen
patient
mani
case
strongli
epidemiolog
link
exposur
typic
lung
radiolog
find
remain
rna
neg
upper
respiratori
tract
sampl
four
potenti
reason
viral
load
upper
respiratori
tract
sampl
much
lower
lower
respiratori
tract
sampl
patient
releas
viral
load
patient
differ
stage
infect
vari
wide
rang
collect
highqual
swab
specimen
requir
skill
healthwork
pcr
reagent
differ
sourc
high
varianc
consequ
problem
lead
noteworthi
delay
earli
diagnosi
follow
manag
propos
seriou
challeng
provid
time
life
support
treatment
prevent
quarantin
mani
known
pathogen
virus
routin
practic
make
diagnosi
acut
infect
accord
serolog
find
long
time
compar
pcr
serolog
test
advantag
faster
turnaround
time
highthroughput
less
workload
howev
clinic
valu
antibodi
larg
depend
understand
host
antibodi
respons
infect
given
newli
emerg
viru
antibodi
respons
patient
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
remain
larg
unknown
mitig
knowledg
gap
provid
scientif
analysi
benefit
antibodi
test
use
combin
current
rna
test
studi
investig
dynam
total
antibodi
ab
igm
igg
antibodi
serial
blood
sampl
collect
confirm
patient
provid
discuss
clinic
valu
antibodi
test
written
inform
consent
obtain
enrol
patient
total
antibodi
ab
igm
antibodi
igg
antibodi
plasma
sampl
test
use
enzym
link
immunosorb
assay
elisa
kit
suppli
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
continu
variabl
descript
mean
standard
deviat
use
normal
distribut
data
median
interquartil
rang
iqr
use
nonnorm
distribut
data
cumul
seroconvers
rate
calcul
kaplanmei
method
associ
antibodi
level
sever
ill
estim
gener
estim
equat
gee
model
logit
link
function
statist
analysi
conduct
sa
sa
institut
cari
nc
usa
funder
role
studi
design
data
collect
data
analysi
data
interpret
write
report
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
among
total
case
patient
admit
hospit
feb
patient
enrol
studi
tabl
tabl
among
critic
ill
condit
ard
oxygen
satur
requir
mechan
ventil
either
invas
noninvas
remain
mild
moder
syndrom
noncrit
condit
februari
total
patient
noncrit
group
critic
group
recov
discharg
hospit
critic
group
patient
die
underli
chronic
diseas
total
plasma
sampl
collect
hospit
period
patient
test
antibodi
seroconvers
rate
ab
igm
igg
respect
tabl
twelv
patient
remain
seroneg
ab
test
possibl
due
sampl
involv
collect
earli
stage
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
ill
earlier
day
two
day
onset
cumul
seroconvers
curv
show
rate
ab
igm
reach
around
month
ill
day
seroconvers
sequenti
appear
ab
igm
igg
figur
median
time
ab
igm
igg
seroconvers
day
separ
one
two
patient
test
onset
day
seroposit
overal
seroconvers
ab
significantli
quicker
igm
p
igg
p
possibl
attribut
doubleantigen
sandwich
form
assay
use
usual
show
much
higher
sensit
captur
assay
igm
indirect
assay
igg
moreov
isotyp
antibodi
viral
antigen
includ
igm
iga
igg
detect
doublesandwich
base
assay
may
also
contribut
superior
perform
ab
test
comparison
seroconvers
rate
antibodi
critic
noncrit
patient
none
three
marker
show
signific
differ
figur
id
p
analyz
detect
rna
test
antibodi
assay
accord
time
cours
sinc
ill
onset
cohort
result
shown
figur
tabl
earli
phase
ill
within
sinc
onset
rna
test
highest
sensit
wherea
antibodi
assay
present
posit
rate
howev
sensit
ab
overtook
rna
test
sinc
day
onset
reach
across
day
onset
figur
sampl
patient
day
onset
sensit
ab
igm
igg
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
detect
antibodi
total
ab
assay
respect
tabl
whatev
combin
use
test
rna
ab
improv
markedli
sensit
pathogenicdiagnosi
patient
differ
phase
tabl
abrna
investig
dynam
antibodi
level
accord
diseas
cours
antibodi
level
express
use
rel
bind
signal
compar
cutoff
valu
assay
sco
longitudin
chang
antibodi
rna
repres
patient
includ
noncrit
group
figur
critic
group
figur
present
figur
first
posit
time
point
rna
test
appear
earlier
ab
patient
except
case
ab
detect
day
earlier
rna
case
day
note
rise
antibodi
alway
accompani
rna
clearanc
particularli
critic
patient
find
suggest
antibodi
may
suffici
clear
viru
pool
analys
involv
patient
averag
antibodi
level
show
mark
increas
sinc
onset
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
continu
elev
next
week
figur
analys
suggest
signific
differ
averag
sco
valu
ab
test
critic
noncrit
patient
day
onset
figur
howev
critic
patient
show
significantli
higher
ab
sco
valu
noncrit
case
onset
p
associ
signific
either
igm
igg
test
data
shown
explor
determin
rel
ab
titer
sampl
express
rel
optic
densiti
rod
serial
dilut
measur
sampl
quantit
data
ab
titer
also
reveal
signific
differ
p
patient
critic
noncrit
group
figur
multivari
longitudin
gee
analys
suggest
age
p
gender
p
ab
titer
p
independ
factor
strongli
associ
clinic
classif
base
sever
tabl
present
data
demonstr
typic
antibodi
respons
acut
viral
infect
wildli
induc
patient
patient
seroconvert
except
patient
sampl
collect
earli
stage
ill
day
onset
expect
total
antibodi
first
detect
follow
igm
igg
seroconvers
rate
antibodi
level
increas
rapidli
first
two
week
cumul
seroposit
rate
reach
day
day
seroconvers
time
total
antibodi
igm
igg
antibodi
appear
consequ
p
median
seroconvers
day
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
thu
antibodi
test
might
play
vital
role
follow
set
suspect
patient
initi
visit
clinic
diagnos
patient
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
confirm
rna
test
posit
result
antibodi
increas
confid
make
diagnosi
healthi
close
contact
quarantin
period
hesh
deem
probabl
carrier
antibodi
posit
rna
test
frequent
close
contact
himher
observ
rna
confirm
patient
seroposit
indic
specif
immun
respons
induc
besid
epidemiolog
studi
could
conduct
use
immunoassay
addit
play
import
role
search
potenti
anim
host
use
abelisa
doubl
antigen
sandwich
method
make
free
speci
restrict
less
three
month
sinc
viru
first
invad
human
societi
preval
antibodi
nearli
zero
therefor
least
current
outbreak
like
continu
may
june
individu
seroposit
could
probabl
preced
infector
short
period
therefor
total
antibodi
could
consid
recent
infect
marker
similar
igm
antibodi
data
show
sensit
total
antibodi
test
higher
igm
igg
therefor
total
antibodi
detect
given
high
prioriti
implement
current
clinic
public
health
practic
unfortun
becom
common
respiratori
transmiss
pathogen
last
human
societi
influenza
virus
lowpathogen
type
coronavirus
rather
complet
erad
rel
viru
serolog
diagnosi
acut
infect
depend
detect
igm
antibodi
postepidem
area
wuhan
china
subsequ
epidem
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
season
total
antibodi
igg
antibodi
could
use
understand
epidemiolog
infect
assist
determin
level
humor
immun
respons
patient
even
total
antibodi
sensit
marker
sentinel
monitor
import
case
naiv
commun
addit
diagnosi
valu
ab
test
studi
reveal
strong
posit
correl
clinic
sever
antibodi
titer
sinc
ill
onset
first
time
patient
result
suggest
high
titer
total
antibodi
viru
may
consid
risk
factor
critic
ill
independ
older
age
male
gender
comorbid
tabl
note
limit
studi
first
rna
test
patient
base
upper
respiratori
tract
specimen
posit
rate
may
higher
detect
use
lower
respiratori
tract
specimen
bronchoalveolar
lavag
fluid
deep
tracheal
aspir
induc
sputum
may
yield
higher
sensit
rna
test
second
evalu
persist
antibodi
sampl
collect
acut
ill
cours
patient
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
third
although
shown
good
specif
healthi
peopl
crossreact
among
differ
coronavirus
accur
assess
obtain
blood
sampl
coronavirus
infect
patient
futur
studi
need
better
understand
antibodi
respons
profil
infect
conclus
find
demonstr
antibodi
test
import
diagnosi
valu
addit
rna
test
find
provid
strong
evid
routin
applic
serolog
antibodi
assay
diagnosi
clinic
manag
patient
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
declar
compet
interest
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
rna
test
use
throatnas
swab
sampl
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
authorfund
grant
medrxiv
licens
display
preprint
perpetu
